Robeco Institutional Asset Management B.V. Increases Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Robeco Institutional Asset Management B.V. lifted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 15.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 516,293 shares of the life sciences company's stock after acquiring an additional 67,676 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.33% of Illumina worth $40,963,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ILMN. Golden State Wealth Management LLC lifted its position in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Lecap Asset Management Ltd. raised its holdings in Illumina by 121.7% during the 1st quarter. Lecap Asset Management Ltd. now owns 47,208 shares of the life sciences company's stock valued at $3,745,000 after buying an additional 25,910 shares during the last quarter. Balboa Wealth Partners bought a new stake in Illumina during the 1st quarter valued at $251,000. Asset Management One Co. Ltd. boosted its position in Illumina by 14.9% during the 1st quarter. Asset Management One Co. Ltd. now owns 111,478 shares of the life sciences company's stock valued at $8,845,000 after buying an additional 14,436 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Illumina by 9.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 7,387 shares of the life sciences company's stock worth $586,000 after purchasing an additional 641 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Up 0.7%

Shares of NASDAQ ILMN traded up $0.63 during trading on Friday, reaching $94.79. The company had a trading volume of 3,837,289 shares, compared to its average volume of 2,142,698. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The business's 50-day moving average is $82.69 and its 200 day moving average is $98.98. The stock has a market cap of $15.01 billion, a PE ratio of -15.62, a P/E/G ratio of 1.86 and a beta of 1.32.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.98 earnings per share. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of Illumina stock in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 2.60% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ILMN shares. Piper Sandler reduced their target price on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Guggenheim cut their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Stephens restated an "overweight" rating and issued a $105.00 price objective on shares of Illumina in a report on Tuesday, May 20th. Robert W. Baird cut their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Finally, Royal Bank Of Canada decreased their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $127.39.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.